Work

Bcl-2 Inhibition or FBXW7 Mutation Sensitizes Solid Tumor Cells to HDAC Inhibition In Vitro but Could Prove Difficult to Validate in Patients

Year: 2013

Type: article

Abstract: Summary: In this issue of Cancer Discovery, He and colleagues determined that Mcl-1 levels are a key factor in the response to histone deacetylase (HDAC) inhibitors, and FBXW7 mutation is a biomarker for sensitivity to HDAC inhibition. They also present evidence for synergy between treatment with HDAC inhibitors and Bcl-2–targeted therapeutics. These data provide an exciting new biomarker and combination therapy that should be evaluated clinically. Cancer Discov; 3(3); 258–9. ©2013 AACR. See related article by He et al., p. 324

Source: Cancer Discovery

DOI: 10.1158/2159-8290.cd-13-0019

Authors: Curtis R. Pickering, Jeffrey N. Myers

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Histone Deacetylase Inhibitors Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2053392380